Therapeutic Response

BRAF p.V600E status confers therapeutic sensitivity to Dabrafenib in combination with Trametinib in patients with High-Grade Glioma, NOS.

Statements

Source and description
Mekinist (trametinib) [product monograph]. HC. Health Canada approved trametinib, as monotherapy or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. Clinical data are stronger for BRAF V600E than V600K.
Tafinlar (dabrafenib) [product monograph]. HC. Health Canada approved dabrafenib mesylate in combination with trametinib for the treatment of pediatric patients 1 year of age and older with high-grade glioma (HGG) with BRAF V600E mutation who have received at least one prior radiation and/or chemotherapy treatment.